
Unprocessed bulk material harvested directly from the bioreactor should be tested for contamination prior to downstream processing.
Unprocessed bulk material harvested directly from the bioreactor should be tested for contamination prior to downstream processing.
Bioconjugation requires aseptic manufacturing and containment for cytotoxic payloads.
Advances in single-use technologies, sensors, and cell retention systems facilitate processes designed for the long run.
The investment builds on a collaboration the companies entered into in 2007 for various biomanufacturing projects.
FDA’s 21st Century goals can be realized by using a multi-purpose manufacturing facility with a flexible design that provides reliable production without extensive regulatory oversight.
A multi-purpose biopharmaceutical manufacturing facility using a matrix of multi-functional cleanrooms can be adapted to efficiently meet the capacity challenges of both supplying clinical trials and launching products.
A matrix of multi-functional cleanrooms can be adapted for launching products.
GE’s new facility, which will be operational in 2019, will produce a fiber-based chromatography platform for more efficient biopharmaceutical purification.
Cobra, Pall, and Cell and Gene Therapy Catapult are collaborating to develop continuous manufacturing for gene therapy production.
The new center will integrate biologics drug discovery, development, clinical manufacturing, and commercial manufacturing.
The vaccine producer announced an expansion to its Holly Springs, NC, manufacturing facility where it will increase production of its cell-based quadrivalent influenza vaccine.
The new collaborative center aims to serve as a hub for innovations in drug development and manufacturing.
Under the new long-term agreement, Sartorius Stedim Biotech will continue to offer Lonza media and buffer products under non-exclusive terms.
Improving the manufacturing of gene therapy vectors will be crucial to making advanced treatments accessible to more patients who need them, agreed panelists at the 2018 Galien Forum.
Experts believe that the contract development and manufacturing organization market will reach $17.38 billion by 2022, with disruptive business models using Industrial Internet of Things (IIot) and single-use technologies proving more profitable and efficient in the long term.
GE Healthcare will collaborate with Wego Pharmaceutical in China for local production and supply of GE Healthcare’s Fortem single-use consumables.
The new program will provide cell and gene therapy companies a more efficient way to ensure quality compliance across collection center networks and to minimize quality system audit burden on these centers.
The expanded Frederick, MD, site will help meet global demand for diagnostic instruments and cell and gene therapies for clinical trials.
The company has rolled out the first batch of TRACON Pharmaceutical’s lead product candidate from its Singapore-based single-use bioreactor.
The expansion adds new capabilities and enhances existing service offerings for both oral and parenteral dosage forms.
New data highlights ability of the SQZ cell therapy platform to preserve cellular functions.
Recent equipment and updated product options offer improvement to a range of biopharmaceutical manufacturing tasks.
Survey results and record attendance may show positive signs for established and emerging biopharma regions.
Platform processes have improved monoclonal antibody scale-up. Can they do the same for personalized therapies?
Industry is searching for ways to deal with the criticality of ensuring data integrity.